statistiche ricercatore

Continente	#
NA - Nord America	319
EU - Europa	285
AS - Asia	282
SA - Sud America	30
AF - Africa	19
Continente sconosciuto - Info sul continente non disponibili	13
OC - Oceania	1
Totale	949

Nazione	#
US - Stati Uniti d'America	296
RU - Federazione Russa	127
SG - Singapore	93
CN - Cina	69
HK - Hong Kong	45
IT - Italia	40
VN - Vietnam	32
GB - Regno Unito	30
DE - Germania	23
FR - Francia	22
BR - Brasile	18
BJ - Benin	14
CA - Canada	10
KR - Corea	10
NL - Olanda	10
IE - Irlanda	6
PL - Polonia	6
UA - Ucraina	6
IN - India	5
BD - Bangladesh	4
FI - Finlandia	4
MX - Messico	4
PH - Filippine	4
AT - Austria	3
ES - Italia	3
ID - Indonesia	3
PE - Perù	3
TH - Thailandia	3
TR - Turchia	3
VE - Venezuela	3
AR - Argentina	2
CW - ???statistics.table.value.countryCode.CW???	2
EC - Ecuador	2
IQ - Iraq	2
JP - Giappone	2
SE - Svezia	2
TT - Trinidad e Tobago	2
ZA - Sudafrica	2
AE - Emirati Arabi Uniti	1
AU - Australia	1
BB - Barbados	1
BE - Belgio	1
CL - Cile	1
CO - Colombia	1
CR - Costa Rica	1
DZ - Algeria	1
EE - Estonia	1
GP - Guadalupe	1
HN - Honduras	1
IL - Israele	1
LT - Lituania	1
MA - Marocco	1
MY - Malesia	1
PK - Pakistan	1
PR - Porto Rico	1
PS - Palestinian Territory	1
SA - Arabia Saudita	1
SN - Senegal	1
SV - El Salvador	1
TC - Turks e Caicos	1
UZ - Uzbekistan	1
Totale	938

Nome	#
Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe	129
Accounting and funding of pharmaceuticals. Purpose, structure and management of the File F in nine Italian regions	101
Early access programs and managed entry agreements for medicines in Italy: Results of a Focus Group (Early Access Programs and Managed Entry Agreement)	96
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service	94
The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study	86
Implementation of Value-based Pricing for Medicines	82
Variations in non-prescription drug consumption and expenditure: Determinants and policy implications	79
De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making	75
The impact of HTA and procurement practices on the selection and prices of medical devices	75
The future of Funds for Innovative Medicines: results from a Delphi Study	66
The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study	66
Totale	949

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2023/2024	67	0	0	24	5	5	0	4	0	0	0	12	17
2024/2025	157	2	0	8	0	10	10	12	29	23	25	6	32
2025/2026	553	27	21	29	48	72	39	87	107	38	33	33	19
2026/2027	172	26	42	25	79	0	0	0	0	0	0	0	0
Totale													949